Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience | Zendy

Emre Bılgın | Zendy; Furkan Ceylan | Zendy; E. Duran | Zendy; B. Farisoğulları | Zendy; E. C. Bolek | Zendy; G. K. Yardimci | Zendy; Levent Kılıç | Zendy; Ali Akdoğan | Zendy; Ömer Karadağ | Zendy; Şule Apraş Bilgen | Zendy; Sedat Kiraz | Zendy; İhsan Ertenli | Zendy; Umut Kalyoncu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience

Author(s) -

Emre Bılgın,

Furkan Ceylan,

E. Duran,

B. Farisoğulları,

E. C. Bolek,

G. K. Yardimci,

Levent Kılıç,

Ali Akdoğan,

Ömer Karadağ,

Şule Apraş Bilgen,

Sedat Kiraz,

İhsan Ertenli,

Umut Kalyoncu

Publication year - 2020

Publication title -

turkish journal of medical sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.277

H-Index - 27

eISSN - 1303-6165

pISSN - 1300-0144

DOI - 10.3906/sag-2007-123

Subject(s) - medicine , tofacitinib , discontinuation , adverse effect , rheumatoid arthritis , concomitant , hazard ratio , retention rate , proportional hazards model , logistic regression , confidence interval , computer security , computer science

To assess the real-life efficacy, retention rate, and safety data of tofacitinib in rheumatoid arthritis (RA) patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research